131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma:: a comparative study
131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma:: a comparative study
复制标题
DOI：
10.1097/00006231-200203000-00005
复制
发表时间：
2002-03-01
影响因子：
1.5
通讯作者：
Corstens, FHM
中科院分区：
文献类型：
--
作者：
Brouwers, AH;Dörr, U;Corstens, FHM
本研究的目的是建立用嵌合单抗I-131-cG250放射免疫显像(RIS)和F-18标记脱氧葡萄糖([F-18]FDG)正电子发射断层扫描(PET)检测转移性肾细胞癌(RCC)病灶的百分比，并评价这两种放射性核素成像方法的应用与常规成像技术的比较。20例转移性肾细胞癌患者在1周内行[F-18]FDG-PET和I-131-cG250 RIS检查。注射232MBq I-131-cG250后120h进行全身伽马摄像。在静脉注射370MBq[F-18]FDG后45~60min进行全身PET扫描。将核医学技术与常规成像程序进行了比较。常规影像检查共发现79个转移瘤。[F-18]FDG-PET和I-131-cG250 RIS检测到33个未知转移灶，其中32个为[F-18]FDG阳性，7个为I-131-cG250阳性。在记录在案的112个肿瘤病变中，[F-18]FDG-PET检测到69%(112个中的77个)，而I-131-cG250 RIS仅检测到30%(112个中的34个)。总之，[F-18]FDG-PET在检测转移性肾癌患者的转移方面优于I-131-cG250 RIS，因此似乎是一种有前途的肾癌患者(重新)分期的工具。诊断剂量为I-131-cG250的RIS的有效性似乎仅限于选择接受I-131-cG250放射免疫治疗的患者。(C)2002年利平科特·威廉姆斯·威尔金斯)。
The aims of this study were to establish the percentage of metastatic renal cell carcinoma (RCC) lesions detected by radioimmunoscintigraphy (RIS) with the chimeric monoclonal antibody I-131-cG250 versus positron emission tomography (PET) with F-18-labelled deoxyglucose ([F-18]FDG), and to evaluate the use of these radionuclide imaging modalities compared with routinely used imaging techniques. Twenty patients with metastatic RCC disease were examined with [F-18]FDG-PET and I-131-cG250 RIS within 1 week. Total body gamma camera images were obtained up to 120 h after injection of 232 MBq I-131-cG250. Total body PET scanning was performed 45-60 min after intravenous injection of 370 MBq [F-18]FDG. Nuclear medicine techniques were compared to routine imaging procedures. Routine imaging modalities revealed a total of 79 metastases. [F-18]FDG-PET and I-131-cG250 RIS detected 33 previously unknown metastases, of which 32 were [F-18]FDG positive and seven were I-131-cG250 positive. Of the 112 tumour lesions that were documented, [F-18]FDG-PET detected 69% (77 out of 112), whereas I-131-cG250 RIS detected only 30% (34 out of 112). In conclusion, [F-18]FDG-PET is superior to I-131-cG250 RIS in detecting metastases in patients with metastatic RCC, and therefore seems a promising tool for (re)staging patients with RCC. The usefulness of RIS with a diagnostic dose of I-131-cG250 seems to be restricted to selecting patients for radioimmunotherapy with I-131-cG250. (C) 2002 Lippincott Williams Wilkins).